CRITICALFEDGLP-1 CompoundingJun 23, 2026

FDA Warning Letter: ketaminelab.org (Drugs)

FDA Warning Letter issued to ketaminelab.org for drugs.

What changed & why it matters

Med Spa Radar recorded an FDA Warning Letter at the federal level, dated June 23, 2026, in the GLP-1 Compounding category.

An FDA Warning Letter is a formal, public notice that a firm's conduct violated federal law. For a med spa it is a supplier-and-marketing signal: it names conduct the FDA considers unlawful, from compounding practices to the health claims a practice might echo.

Type
FDA Warning Letter
Jurisdiction
Federal
Category
GLP-1 Compounding
Recorded
June 23, 2026

What this means for your specific practice — the exact step to take, the deadline to calendar, or the supplier detail to check — is in the member "what to do" below. This page is the free record of what changed and why it matters.

What to do

Free weekly Brief

Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.

Members get the full “what to do” on every alert — in real time, for your states. Become a member →

FDA Warning Letter · primary source ↗

Related alerts

Monitoring, not legal advice.